Our Core Values:


We demonstrate the value we hold for one another.

  • Act with respect towards our colleagues and others with whom we interact.
  • Communicate openly and candidly and address our differences professionally.
  • Emphasise teamwork, value each person’s contribution and collaborate in confidence and trust.
  • Look for the strengths people bring to the team.


We do what is right.

  • Conduct our business with individual and organizational integrity.
  • Comply with the law and avoid conflicts of interest.
  • We are reliable, honest and trustworthy in our dealings.
  • Every day you are asked to follow procedures, make decisions, show leadership and develop others, do this with integrity and lead by example.


We hold ourselves accountable for our actions.

  • We accept personal responsibility for everything that we do and we lead by example.
  • We treat the Company’s reputation as our own.

Our Strategy:

  • The first new chemical entity in a generation to treat patients with glaucoma
  • Designed to reduce elevated intraocular pressure (IOP), the cause of vision loss in open-angle glaucoma
  • One approved product – Rhopressa® (netarsudil ophthalmic solution) 0.02% and one late development-stage product – Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
  • Both product candidates are eye drops taken once a day in the evening
  • Each product candidate has potential multiple mechanisms of action, including the novel targeting of the diseased tissue, or main drain in the eye – the source of elevated IOP; potential for disease modification
  • Significant potential in an approximately $5 billion market in the U.S., Europe and Japan, which is expected to grow to more than $8 billion by 2023All product candidates fully owned by Aerie with patents through to at least 2030

Return to Aerie jobs